UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL–Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group

Journal of clinical oncology, 2006-01, Vol.24 (3), p.460-466

2006

Volltextzugriff (PDF)

Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study

Cancer science, 2012-06, Vol.103 (6), p.1071-1078

2012

Volltextzugriff (PDF)

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study

International journal of hematology, 2010-03, Vol.91 (2), p.284-292

2010

Volltextzugriff (PDF)

Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study

International journal of hematology, 2012-07, Vol.96 (1), p.84-93

2012

Volltextzugriff (PDF)

Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome

European journal of haematology, 2007-03, Vol.78 (3), p.213-219

2007

Volltextzugriff (PDF)

Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study

International journal of hematology, 2010-10, Vol.92 (3), p.490-502

2010

Volltextzugriff (PDF)

Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group

International journal of hematology, 2010-01, Vol.91 (1), p.97-103

2010

Volltextzugriff (PDF)

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study

International journal of hematology, 2010-03, Vol.91 (2), p.276-283

2010

Volltextzugriff (PDF)

Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy

Haematologica (Roma), 2008-02, Vol.93 (2), p.287-290

2008

Volltextzugriff (PDF)

A novel gene, ANKRD28 on 3p25, is fused with NUP98 on 11p15 in a cryptic 3-way translocation of t(3;5;11 ) (p25;q35;p15) in an adult patient with myelodysplastic syndrome/acute myelogenous leukemia

International journal of hematology, 2007-10, Vol.86 (3), p.238-245

2007

Volltextzugriff (PDF)

Cas-L was over-expressed in imatinib-resistant gastrointestinal stromal tumor cells

Cancer biology & therapy, 2009-04, Vol.8 (8), p.683-688

2009

Volltextzugriff (PDF)

Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)

Leukemia & lymphoma, 2006-10, Vol.47 (10), p.2062-2069

2006

Volltextzugriff (PDF)

Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study

International journal of hematology, 2008-03, Vol.87 (2), p.195-202

2008

Volltextzugriff (PDF)

Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

Blood, 2009-12, Vol.114 (26), p.5271-5278

2009

Volltextzugriff (PDF)

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia

Blood, 2005-10, Vol.106 (8), p.2854-2861

2005

Volltextzugriff (PDF)

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

Blood, 2001-04, Vol.97 (8), p.2434-2439

2001

Volltextzugriff (PDF)

Prospective monitoring of BCR‐ABL1 transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapy

British journal of haematology, 2008-11, Vol.143 (4), p.503-510

2008

Volltextzugriff (PDF)

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL–positive acute lymphoblastic leukemia

Blood, 2004-12, Vol.104 (12), p.3507-3512

2004

Volltextzugriff (PDF)

Safety and efficacy of zoledronic acid in multiple myeloma

The Lancet (British edition), 2011-06, Vol.377 (9784), p.2178-2178

2011

Volltextzugriff (PDF)

Eltrombopag for chronic immune thrombocytopenia

The Lancet (British edition), 2011-06, Vol.377 (9781), p.1919-1919

2011

Volltextzugriff (PDF)

Multicenter prospective study of interferon α versus allogeneic stem cell transplantation for patients with new diagnoses of chronic myelogenous leukemia

International journal of hematology, 2004-05, Vol.79 (4), p.345-353

2004

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(104)

Publikationsform

Artikel
(119)

Sprache

Englisch
(105)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Humans
(63)
Life Sciences & Biomedicine
(48)
Science & Technology
(48)
Male
(40)
Middle Aged
(40)
Female
(35)
Adult
(33)
Hematology
(32)
Biological And Medical Sciences
(28)
Medical Sciences
(28)
Hematologic And Hematopoietic Diseases
(24)
Aged
(23)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(22)
Oncology
(20)
Treatment Outcome
(17)
Adolescent
(16)
Survival Analysis
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Remission Induction
(11)
Aged, 80 And Over
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL–Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group

A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study

Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study

Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study

Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome

Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study

Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study

Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy

Efficacy of Gemtuzumab Ozogamicin (GO) Monotherapy on Relapsed/Refractory Acute Promyelocytic Leukemia (APL)

A novel gene, ANKRD28 on 3p25, is fused with NUP98 on 11p15 in a cryptic 3-way translocation of t(3;5;11 ) (p25;q35;p15) in an adult patient with myelodysplastic syndrome/acute myelogenous leukemia

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

Cas-L was over-expressed in imatinib-resistant gastrointestinal stromal tumor cells

Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)

Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study

A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study

Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

Prospective monitoring of BCR‐ABL1 transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapy

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL–positive acute lymphoblastic leukemia

Safety and efficacy of zoledronic acid in multiple myeloma

Eltrombopag for chronic immune thrombocytopenia

Multicenter prospective study of interferon α versus allogeneic stem cell transplantation for patients with new diagnoses of chronic myelogenous leukemia

Suchergebnisse filtern